Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Equity Average (2016 - 2023)

Rapid Therapeutic Science Laboratories' Equity Average history spans 8 years, with the latest figure at -$2.8 million for Q2 2023.

  • For Q2 2023, Equity Average rose 4.85% year-over-year to -$2.8 million; the TTM value through Jun 2023 reached -$2.8 million, up 4.85%, while the annual FY2022 figure was -$2.3 million, 224.72% down from the prior year.
  • Equity Average for Q2 2023 was -$2.8 million at Rapid Therapeutic Science Laboratories, up from -$3.0 million in the prior quarter.
  • Across five years, Equity Average topped out at $636936.0 in Q2 2021 and bottomed at -$3.3 million in Q3 2019.
  • The 5-year median for Equity Average is -$2.2 million (2019), against an average of -$1.8 million.
  • The largest annual shift saw Equity Average surged 146.91% in 2021 before it plummeted 2716.57% in 2022.
  • A 5-year view of Equity Average shows it stood at -$2.3 million in 2019, then skyrocketed by 89.12% to -$252813.0 in 2020, then plummeted by 206.29% to -$774353.5 in 2021, then plummeted by 302.17% to -$3.1 million in 2022, then increased by 10.46% to -$2.8 million in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Equity Average are -$2.8 million (Q2 2023), -$3.0 million (Q1 2023), and -$3.1 million (Q4 2022).